Fig. 4.

Clinical outcomes of Stage IV patients treated with anti-EGFR therapies. a Waterfall plot for 33 patients with Stage IV CRC after anti-EGFR targeted therapy in addition to cytotoxic chemotherapy. The vertical axis shows the best calculated responses on the basis of measurable lesions in each individual patient. b Swimmers plot for 39 patients with Stage IV CRC treated with anti-EGFR therapies. The horizontal axis shows progression-free survival for each patient. c, d Kaplan–Meier survival estimates according to genomic subgroups. c Progression-free survival was analyzed in 39 patients with Stage IV CRC treated with anti-EGFR therapies. The patients were divided to “All WT (wild type)” (Cluster 1; n = 15) or “Mutated” (Clusters 2–8; n = 24) based on the cluster analysis with targeted therapy-related 26 genes. d Progression-free survival was analyzed for 36 patients with Stage IV CRC treated with anti-EGFR therapies based on subgroups (All WT, cluster 1; RNF and BRAF, cluster 4; PTEN, cluster 5; RAS, cluster 6) by clustering with the 26 genes